UC
MCID: ULC004
MIFTS: 75

Ulcerative Colitis (UC)

Categories: Gastrointestinal diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ulcerative Colitis

MalaCards integrated aliases for Ulcerative Colitis:

Name: Ulcerative Colitis 11 42 75 41 14 36 16 71 31 33
Left Sided Ulcerative Colitis 71 33
Colitis Gravis 42 33
Inflammatory Bowel Disease, Ulcerative Colitis Type 42
Chronic Left-Sided Ulcerative Colitis 71
Ulcerative Mucosal Proctocolitis 33
Left-Sided Ulcerative Colitis 11
Chronic Ulcerative Enteritis 33
Uc - [ulcerative Colitis] 33
Idiopathic Proctocolitis 42
Mucosal Proctocolitis 33
Colitis, Ulcerative 43
Colitis Ulcerative 53
Left Hemicolitis 33
Uc 42

Classifications:



External Ids:

Disease Ontology 11 DOID:8577
ICD9CM 34 556 556.5
MeSH 43 D003093
NCIt 49 C2952
SNOMED-CT 68 196988003 441971007
ICD10 31 K51 K51.9
UMLS 71 C0009324 C0375359 C2919576

Summaries for Ulcerative Colitis

MedlinePlus Genetics: 42 Ulcerative colitis is a chronic disorder that affects the digestive system. This condition is characterized by abnormal inflammation of the inner surface of the rectum and colon, which make up most of the length of the large intestine. The inflammation usually causes open sores (ulcers) to develop in the large intestine. Ulcerative colitis usually appears between ages 15 and 30, although it can develop at any age. The inflammation tends to flare up multiple times throughout life, which causes recurring signs and symptoms.The most common symptoms of ulcerative colitis are abdominal pain and cramping and frequent diarrhea, often with blood, pus, or mucus in the stool. Other signs and symptoms include nausea, loss of appetite, fatigue, and fevers. Chronic bleeding from the inflamed and ulcerated intestinal tissue can cause a shortage of red blood cells (anemia) in some affected individuals. People with this disorder have difficulty absorbing enough fluids and nutrients from their diet and often experience weight loss. Affected children usually grow more slowly than normal. Less commonly, ulcerative colitis causes problems with the skin, joints, eyes, kidneys, or liver, which are most likely due to abnormal inflammation.Toxic megacolon is a rare complication of ulcerative colitis that can be life-threatening. Toxic megacolon involves widening of the colon and an overwhelming bacterial infection (sepsis). Ulcerative colitis also increases the risk of developing colon cancer, especially in people whose entire colon is inflamed and in people who have had ulcerative colitis for 8 or more years.Ulcerative colitis is one common form of inflammatory bowel disease (IBD). Another type of IBD, Crohn disease, also causes chronic inflammation of the intestines. Unlike ulcerative colitis, which affects only the inner surface of the large intestine, Crohn disease can cause inflammation in any part of the digestive system, and the inflammation extends deeper into the intestinal tissue.

MalaCards based summary: Ulcerative Colitis, also known as left sided ulcerative colitis, is related to inflammatory bowel disease 1 and pouchitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Ulcerative Colitis is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Magnesium citrate and Ciprofloxacin have been mentioned in the context of this disorder. Affiliated tissues include Bone, colon and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and growth/size/body region

MedlinePlus: 41 Ulcerative colitis (UC) is a disease that causes inflammation and sores, called ulcers, in the lining of the rectum and colon. It is one of a group of diseases called inflammatory bowel disease. UC can happen at any age, but it usually starts between the ages of 15 and 30. It tends to run in families. The most common symptoms are pain in the abdomen and blood or pus in diarrhea. Other symptoms may include: Anemia Severe tiredness Weight loss Loss of appetite Bleeding from the rectum Sores on the skin Joint pain Growth failure in children About half of people with UC have mild symptoms. Doctors use blood tests, stool tests, colonoscopy or sigmoidoscopy, and imaging tests to diagnose UC. Several types of drugs can help control it. Some people have long periods of remission, when they are free of symptoms. In severe cases, doctors must remove the colon. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Disease Ontology: 11 A colitis that is predominantly confined to the mucosa located in colon and includes characteristic ulcers, or open sores.

Wikipedia: 75 Ulcerative colitis (UC) is a long-term condition that results in inflammation and ulcers of the colon... more...

Related Diseases for Ulcerative Colitis

Diseases related to Ulcerative Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1667)
# Related Disease Score Top Affiliating Genes
1 inflammatory bowel disease 1 33.9 TNF TLR2 NOD2 IL23R IL1B IL10
2 pouchitis 32.9 TNF NOD2
3 cholangitis, primary sclerosing 32.8 TNF NOD2 IL4 IL1B IL10 HLA-DRB1
4 pyoderma gangrenosum 32.8 TNF NOD2 IL1B
5 crohn's disease 32.7 TNF TLR2 REG4 NOD2 IL4 IL23R
6 colitis 32.7 TNF TLR2 STAT6 ST6GALNAC1 REG4 NOD2
7 bowel dysfunction 32.6 TNF NOD2 IL1B IL10
8 chemical colitis 32.5 TNF NOD2 IL1B IL10
9 cholangitis 32.5 TNF NOD2 IL2 IL10 HLA-DRB1
10 inflammatory bowel disease 32.4 TNF TLR2 STAT6 ST6GALNAC1 REG4 NOD2
11 pyoderma 32.2 TNF NOD2 IL1B
12 common cold 32.2 TNF IL4 IL2 IL1B IL13 IL10
13 diarrhea 32.1 TNF NOD2 IL2 IL1B IL13 IL10
14 colonic benign neoplasm 32.1 TNF MLH1 IL1B IL10
15 crohn's colitis 32.0 TNF NOD2 IL1B IL10
16 vasculitis 32.0 TNF IL1B IL10 HLA-DRB1
17 irritable bowel syndrome 32.0 TNF TLR2 IL4 IL1B IL10
18 ileitis 32.0 TNF TLR2 NOD2 IL10
19 spondyloarthropathy 1 31.8 TNF NOD2 IL23R IL1B IL10
20 dysentery 31.8 TNF IL1B IL10
21 appendicitis 31.8 TNF IL2 IL1B IL10 IFNG
22 takayasu arteritis 31.8 TNF IL23R IL10 HLA-DRB1
23 herpes zoster 31.7 TLR2 IL2 IL10 IFNG HLA-DRB1
24 enterocolitis 31.7 TNF NOD2 IL10
25 autoimmune disease 31.7 TNF IL4 IL23R IL2 IL1B IL13
26 purpura 31.7 TNF IL4 IL2 IL1B IL10 IFNG
27 spondylitis 31.7 TNF NOD2 IL23R IL1B IL10 IFNG
28 erythema nodosum 31.6 TNF NOD2 IL1B IL13 IL10 IFNG
29 ileus 31.6 TNF IL1B IL10 IFNG
30 proteasome-associated autoinflammatory syndrome 1 31.6 TNF TLR2 IL4 IL1B IL13 IL10
31 gastritis 31.6 TNF IL4 IL1B IL10
32 exanthem 31.6 TNF IL4 IL2 IL1B IL10 IFNG
33 autoimmune hepatitis 31.6 TNF IL10 IFNG HLA-DRB1
34 allergic disease 31.6 TNF IL4 IL2 IL1B IL13 IL10
35 hypereosinophilic syndrome 31.5 IL4 IL2 IL13 IL10 IFNG
36 pericarditis 31.5 TNF IL1B IFNG
37 bronchiectasis 31.5 TNF TLR2 IL1B IFNG
38 celiac disease 1 31.5 TNF TLR2 NOD2 IL4 IL23R IL2
39 peptic ulcer disease 31.5 TNF IL1B IL10
40 primary biliary cholangitis 31.5 TNF IL4 IL2 IL1B IL10 HLA-DRB1
41 myocarditis 31.5 TNF IL4 IL2 IL1B IL10 IFNG
42 amebiasis 31.4 TNF TLR2 IL4 IL1B IL10
43 pneumonia 31.4 TNF TLR2 IL4 IL1B IL13 IL10
44 duodenal ulcer 31.4 TNF IL1B IL10 HLA-DRB1
45 sarcoidosis 1 31.4 TNF NOD2 IL2 IL1B IL13 IL10
46 alopecia 31.4 TNF IL4 IL2 IL1B IFNG HLA-DRB1
47 uveitis 31.4 TNF NOD2 IL4 IL23R IL2 IL1B
48 microscopic colitis 31.4 TNF IL1B IL10
49 acne 31.4 TNF TLR2 IL1B IL10
50 gastroenteritis 31.4 TNF IL4 IL1B IL10 IFNG

Comorbidity relations with Ulcerative Colitis via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Hypothyroidism
Inflammatory Bowel Disease 1 Intestinal Obstruction
Iron Deficiency Anemia Paralytic Ileus
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Ulcerative Colitis:



Diseases related to Ulcerative Colitis

Symptoms & Phenotypes for Ulcerative Colitis

UMLS symptoms related to Ulcerative Colitis:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.47 IL10 IL1B MLH1 NFKB1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.47 IL10 IL1B IL2 MLH1 NFKB1 NOD2
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-3 9.47 MLH1 NFKB1

MGI Mouse Phenotypes related to Ulcerative Colitis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.31 ABCB1 HLA-DRB1 IFNG IL10 IL13 IL1B
2 homeostasis/metabolism MP:0005376 10.3 ABCB1 IFNG IL10 IL13 IL1B IL2
3 endocrine/exocrine gland MP:0005379 10.22 ABCB1 IFNG IL10 IL13 IL2 IL23R
4 immune system MP:0005387 10.17 ABCB1 IFNG IL10 IL13 IL1B IL2
5 neoplasm MP:0002006 10.16 IFNG IL10 IL1B IL2 IL23R MLH1
6 digestive/alimentary MP:0005381 10.15 ABCB1 IFNG IL10 IL13 IL2 IL23R
7 liver/biliary system MP:0005370 10.13 ABCB1 IFNG IL10 IL2 IL4 NFKB1
8 no phenotypic analysis MP:0003012 10.1 ABCB1 IFNG IL10 IL13 IL2 IL23R
9 respiratory system MP:0005388 9.96 IFNG IL10 IL13 IL2 IL4 MLH1
10 skeleton MP:0005390 9.85 HLA-DRB1 IFNG IL10 IL13 IL1B IL4
11 hematopoietic system MP:0005397 9.8 ABCB1 IFNG IL10 IL13 IL1B IL2
12 integument MP:0010771 9.32 IFNG IL10 IL13 IL1B IL4 MLH1

Drugs & Therapeutics for Ulcerative Colitis

Drugs for Ulcerative Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 353)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Magnesium citrate Approved Phase 4 3344-18-1
2
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1, 93107-08-5 2764
3
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Linaclotide Approved Phase 4 851199-59-2 16158208
6
Hydrocortisone succinate Approved Phase 4 2203-97-6 3643
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 3640 5754
9
Infliximab Approved Phase 4 170277-31-3
10
Golimumab Approved Phase 4 476181-74-5
11
Mercaptopurine Approved Phase 4 50-44-2 667490
12
Certolizumab pegol Approved Phase 4 428863-50-7
13
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
14
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
16
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
17
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
20
Ozanimod Approved, Investigational Phase 4 1306760-87-1 25110515 52938427
21
Mesalazine Approved Phase 4 89-57-6 4075
22
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
23
Azathioprine Approved Phase 4 446-86-6 2265
24
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
25
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
26
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
27 Cathartics Phase 4
28 Laxatives Phase 4
29 Picosulfate sodium Phase 4
30 Calcineurin Inhibitors Phase 4
31 Cyclosporins Phase 4
32 Vaccines Phase 4
33 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
34 Chrysarobin Phase 4
35 Hydrocortisone 17-butyrate 21-propionate Phase 4
36 Immunologic Factors Phase 4
37 Hormone Antagonists Phase 4
38 polysaccharide-K Phase 4
39
Methylprednisolone Acetate Phase 4 584547
40 glucocorticoids Phase 4
41 Antineoplastic Agents, Hormonal Phase 4
42 Neuroprotective Agents Phase 4
43 Antiemetics Phase 4
44 Bronchodilator Agents Phase 4
45 Anti-Asthmatic Agents Phase 4
46 Analgesics Phase 4
47 Protein Kinase Inhibitors Phase 4
48 Immunosuppressive Agents Phase 4
49 Tumor Necrosis Factor Inhibitors Phase 4
50 Anticonvulsants Phase 4

Interventional clinical trials:

(show top 50) (show all 1234)
# Name Status NCT ID Phase Drugs
1 GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC). Unknown status NCT02687724 Phase 4 Golimumab (GLM)
2 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
3 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial Unknown status NCT02962245 Phase 4 berberine;regular treatment
4 Exposure-response of Golimumab During Maintenance in Ulcerative Colitis: An Exploratory Pharmacokinetics/Pharmacodynamics Comparison of Different Dose Regimens Unknown status NCT04156984 Phase 4 Golimumab Prefilled Syringe
5 Optimization of Golimumab Treatment in Ulcerative Colitis Unknown status NCT03669029 Phase 4 Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg;Golimumab treatment optimization.
6 Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab Unknown status NCT03151525 Phase 4 Azathioprine;Infliximab
7 Tolerability and Efficacy of Low-Volume Sodium Picosulfate/Magnesium Citrate Versus 2L Polyethylene Glycol/Ascorbic Acid in Patients With Ulcerative Colitis Undergoing Colonoscopy: A Randomized Controlled Trial Unknown status NCT03581149 Phase 4 Sodium Picosulfate/Magnesium Citrate Laxative;2L polyethylene glycol/ascorbic acid
8 Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis Unknown status NCT04006080 Phase 4
9 A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC) Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
10 Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis Unknown status NCT02412085 Phase 4 Golimumab
11 Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi) Unknown status NCT02186886 Phase 4 Golimumab
12 Probiotic for the Restoration of Intestinal Permeability and Reduction of Intestinal Inflammation in Active Ulcerative Colitis: A Double Blind Randomized Placebo Controlled Trial Unknown status NCT01479660 Phase 4 Probiotic
13 The Effect of Probiotics on Bowel Disease Unknown status NCT01078935 Phase 4
14 A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology Unknown status NCT02910375 Phase 4
15 Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission. Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
16 A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
17 A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
18 Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis. Completed NCT01941589 Phase 4 oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone;corticosteroids only
19 Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis Completed NCT02092285 Phase 4 Golimumab
20 An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study) Completed NCT02646657 Phase 4 Vedolizumab 300 mg
21 Test Treat Strategy to Prevent Ulcerative Colitis Relapse Completed NCT00652145 Phase 4 mesalamine
22 An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically Completed NCT02559713 Phase 4 Vedolizumab
23 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
24 A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET) Completed NCT03029143 Phase 4 Vedolizumab IV
25 Use of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study Completed NCT02345733 Phase 4 Antibiotic cocktail
26 A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine Once Daily in Adult Subjects With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
27 Open Label Safety and Efficacy Trial of Twice Daily Dosing of Asacol vs. Three Times Per Day Dosing for the Induction of Remission in Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
28 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
29 An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab. Completed NCT02318667 Phase 4
30 Multicentre Investigation of the Efficacy and Safety of Adacolumn® GMA in Patients With Steroid-Dependent Active Ulcerative Colitis and Insufficient Response or Intolerance to Immunosuppressants and/or Biological Therapies Completed NCT01481142 Phase 4
31 A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment. Completed NCT04969679 Phase 4 E. coli Nissle 1917 (Mutaflor®);Placebo
32 Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis. Completed NCT01536535 Phase 4 Mesalazine;IV Corticosteroid;Oral Corticosteroids
33 A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) Completed NCT01804166 Phase 4 Infliximab;Golimumab
34 Multi Center Ulcerative Colitis Pediatric Pentasa Intervention Trial (MUPPIT). A Randomized, Single-blinded, Controlled, Parallel, Induction Therapy With Once vs. Twice Daily Dosing of Pentasa in Pediatric UC. Completed NCT01201122 Phase 4 Mesalamine
35 Histological and Endoscopic Evaluation of Remission Induced by Infliximab in Moderately to Severely Active Ulcerative Colitis Patients Completed NCT01408810 Phase 4 Infliximab
36 Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
37 Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
38 Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial Completed NCT04775732 Phase 4
39 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
40 The Influence of 5-Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
41 Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Completed NCT03124121 Phase 4 Golimumab
42 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
43 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease: A Prospective, Randomized, Double-Blind, Controlled Trial Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
44 Immunogenicity of Hepatitis A Vaccine in Patients With Inflammatory Bowel Disease Completed NCT01341808 Phase 4
45 A Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
46 Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
47 An Open-label Randomized Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating adaLimumab: The CONTROL Trial Recruiting NCT04183608 Phase 4 Adalimumab
48 Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis Recruiting NCT04231110 Phase 4
49 VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target Recruiting NCT04259138 Phase 4
50 EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis : A Double Blinded Randomized Clinical Trial Recruiting NCT03679546 Phase 4 Infliximab;Vedolizumab Injection

Search NIH Clinical Center for Ulcerative Colitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Azathioprine
balsalazide
Balsalazide disodium
Hydrocortisone
hydrocortisone acetate
HYDROCORTISONE ACETATE PWDR
HYDROCORTISONE ACETONIDE
Hydrocortisone butyrate
hydrocortisone cypionate
hydrocortisone probutate
HYDROCORTISONE PWDR
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
hydrocortisone valerate
HYDROCORTISONE,NONSTERILE PWDR
mesalamine
nicotine polacrilex
olsalazine
Olsalazine sodium
Psyllium
PSYLLIUM HYDROCOLLOID
Sulfasalazine

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Ulcerative Colitis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: colitis, ulcerative

Genetic Tests for Ulcerative Colitis

Anatomical Context for Ulcerative Colitis

Organs/tissues related to Ulcerative Colitis:

FMA: Colon
MalaCards : Colon, Bone Marrow, Liver, Skin, Kidney, Bone, T Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Ulcerative Colitis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate

Publications for Ulcerative Colitis

Articles related to Ulcerative Colitis:

(show top 50) (show all 30316)
# Title Authors PMID Year
1
Pilot trial of iBDecide: Evaluating an online tool to facilitate shared decision making for adolescents and young adults with ulcerative colitis. 62 41
36161973 2022
2
Improving Food-Related Quality of Life in Inflammatory Bowel Disease through a Novel Web Resource: A Feasibility Randomised Controlled Trial. 41
36296976 2022
3
Efficacy of the Panax Notoginseng Ejiao Suppository in the Treatment of Patients with Ulcerative Proctitis and Its Effect on Inflammatory Response and Immune Function. 41
36188425 2022
4
STAT4 gene influences genetic predisposition to ulcerative colitis but not Crohn's disease in the Spanish population: a replication study. 53 62
20153791 2010
5
TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons. 53 62
20427396 2010
6
Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. 53 62
19924809 2010
7
Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. 53 62
20454450 2010
8
High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. 53 62
19714749 2010
9
Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. 53 62
20065946 2010
10
Delayed resolution of acute inflammation in ulcerative colitis is associated with elevated cytokine release downstream of TLR4. 53 62
20360984 2010
11
Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. 53 62
19926618 2010
12
MICB0106 gene polymorphism is associated with ulcerative colitis in central China. 53 62
19662431 2010
13
Activation of epithelial STAT3 regulates intestinal homeostasis. 53 62
20160497 2010
14
Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. 53 62
19936899 2010
15
A new natural angelica polysaccharide based colon-specific drug delivery system. 53 62
19408300 2009
16
Decreased sigmoidal ABCB1 (P-glycoprotein) expression in ulcerative colitis is associated with disease activity. 53 62
19958093 2009
17
Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. 53 62
20136960 2009
18
The relationship between the expression of the glucocorticoid receptor in biopsied colonic mucosa and the glucocorticoid responsiveness of ulcerative colitis patients. 53 62
19646928 2009
19
Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn's disease. 53 62
19632232 2009
20
Decreased Toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. 53 62
20083854 2009
21
Down-regulation of protein and mRNA expression of IL-8 and ICAM-1 in colon tissue of ulcerative colitis patients by partition-herb moxibustion. 53 62
19083096 2009
22
[IL-6 and TNF-α gene expression in the rectal mucosal of patients with chronic idiopathic ulcerative colitis and controls]. 53 62
20423763 2009
23
Frequency of single nucleotide polymorphisms in NOD1 gene of ulcerative colitis patients: a case-control study in the Indian population. 53 62
19723304 2009
24
DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. 53 62
19758145 2009
25
Genetics of ulcerative colitis: the come-back of interleukin 10. 53 62
19671546 2009
26
HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. 53 62
19758229 2009
27
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. 53 62
19408340 2009
28
Reduction of interleukin-6, interleukin-8, and anti-phosphatidylserine-prothrombin complex antibody by granulocyte and monocyte adsorption apheresis in a patient with pyoderma gangrenosum and ulcerative colitis. 53 62
19727102 2009
29
DNA-driven nutritional therapy of inflammatory bowel disease. 53 62
19647622 2009
30
[The cytokines in inflammatory bowel disease]. 53 62
19724079 2009
31
[Association of cytotoxic T lymphocyte antigen-4 promoter C-658T polymorphism with ulcerative colitis in Chinese]. 53 62
20017310 2009
32
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. 53 62
19291780 2009
33
Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. 53 62
19701972 2009
34
Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. 53 62
19592695 2009
35
In situ evidence of involvement of Schwann cells in ulcerative colitis: autocrine and paracrine signaling by A disintegrin and metalloprotease-17-mediated tumor necrosis factor alpha production. 53 62
19376560 2009
36
The effect of a new symbiotic formulation on plasma levels and peripheral blood mononuclear cell expression of some pro-inflammatory cytokines in patients with ulcerative colitis: a pilot study. 53 62
19694343 2009
37
Genetic polymorphisms of interleukin 8 and risk of ulcerative colitis in the Chinese population. 53 62
19348790 2009
38
Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. 53 62
19528350 2009
39
Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. 53 62
19617917 2009
40
Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. 53 62
19455129 2009
41
Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. 53 62
19303021 2009
42
Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. 53 62
19491856 2009
43
Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. 53 62
19617644 2009
44
Promoter methylation of protease-activated receptor (PAR2) is associated with severe clinical phenotypes of ulcerative colitis (UC). 53 62
19184329 2009
45
The combination of polymorphisms within MCP-1 and IL-1beta associated with ulcerative colitis. 53 62
19392835 2009
46
PPARgamma agonists as a new class of effective treatment for ulcerative colitis. 53 62
18798571 2009
47
Cytotoxic T lymphocyte antigen-4 promoter -658CT gene polymorphism is associated with ulcerative colitis in Chinese patients. 53 62
19089435 2009
48
GlcNAc6ST-1-mediated decoration of MAdCAM-1 protein with L-selectin ligand carbohydrates directs disease activity of ulcerative colitis. 53 62
19067429 2009
49
Epithelial tight junctions in intestinal inflammation. 53 62
19538319 2009
50
[TNF alfa polymorphism and course of ulcerative colitis]. 53 62
19606693 2009

Variations for Ulcerative Colitis

Expression for Ulcerative Colitis

LifeMap Discovery
Genes differentially expressed in tissues of Ulcerative Colitis patients vs. healthy controls: 35 (show all 12)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CLDN8 claudin 8 Colon - 4.72 0.000
2 LCN2 lipocalin 2 Colon + 4.60 0.000
3 REG3A regenerating family member 3 alpha Colon + 4.41 0.001
4 SLC26A2 solute carrier family 26 member 2 Colon - 4.19 0.000
5 PCK1 phosphoenolpyruvate carboxykinase 1 Colon - 4.13 0.000
6 CXCL8 C-X-C motif chemokine ligand 8 Colon + 3.86 0.003
7 CXCL2 C-X-C motif chemokine ligand 2 Colon + 3.85 0.000
8 REG1A regenerating family member 1 alpha Colon + 3.68 0.005
9 RGS3 regulator of G protein signaling 3 Colon + 3.58 0.000
10 CXCL1 C-X-C motif chemokine ligand 1 Colon + 3.55 0.000
11 OLFM4 olfactomedin 4 Colon + 3.25 0.014
12 DEFA6 defensin alpha 6 Colon + 3.22 0.003
Search GEO for disease gene expression data for Ulcerative Colitis.

Pathways for Ulcerative Colitis

Pathways related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TNF TLR2 STAT6 NOD2 NFKB1 IL4
2
Show member pathways
13.87 IL10 IL13 IL1B IL2 IL23R IL4
3
Show member pathways
13.68 IFNG IL10 IL13 IL1B IL2 IL23R
4
Show member pathways
13.6 TNF STAT6 NFKB1 IL4 IL2 IL1B
5
Show member pathways
13.53 TNF TLR2 STAT6 NFKB1 IL4 IL2
6
Show member pathways
13.47 TNF TLR2 STAT6 NFKB1 IL4 IL23R
7
Show member pathways
13.41 HLA-DRB1 IFNG IL10 IL13 IL1B IL2
8
Show member pathways
13.37 TNF NFKB1 IL4 IL23R IL2 IL1B
9
Show member pathways
12.93 TNF STAT6 NFKB1 IL4 IL2 HLA-DRB1
10
Show member pathways
12.88 TNF TLR2 NFKB1 IL2 IL1B
11
Show member pathways
12.8 TNF IL2 IL1B IFNG ABCB1
12
Show member pathways
12.76 TNF TLR2 NFKB1 IL2 IL1B
13
Show member pathways
12.74 TNF STAT6 IL4 IL23R IL2 IL1B
14
Show member pathways
12.71 IFNG IL10 IL1B IL2 IL23R NFKB1
15 12.66 IFNG IL10 IL1B IL2 IL4 NFKB1
16
Show member pathways
12.6 IL1B NFKB1 NOD2 TLR2 TNF
17
Show member pathways
12.56 NOD2 NFKB1 IL4 IL1B IL13
18
Show member pathways
12.52 TNF TLR2 NFKB1 IL4 IL1B IFNG
19
Show member pathways
12.47 NFKB1 IL2 IL1B IL13
20
Show member pathways
12.35 TNF NFKB1 IL1B IFNG
21 12.29 TNF TLR2 NFKB1 MLH1 IFNG
22 12.27 TNF NFKB1 IL1B IL13 IL10
23
Show member pathways
12.26 TNF IL4 IL2 IFNG
24
Show member pathways
12.24 TNF NFKB1 IL4 IL23R IL2 IL10
25 12.18 TNF STAT6 NFKB1 IL4 IL1B IL13
26
Show member pathways
12.14 IL13 IL1B IL2 NFKB1 TLR2
27 12.11 TNF IL4 IL2 IL10 IFNG
28 12.11 TNF IL4 IL2 IL1B IFNG
29
Show member pathways
12.11 STAT6 NFKB1 IL4 IL2 IL1B IFNG
30
Show member pathways
12.1 NFKB1 IL4 IL2 IFNG
31 12.1 TNF STAT6 IL4 IL23R IL1B IL13
32
Show member pathways
12.02 TNF TLR2 IL23R IL2 IL1B IL10
33
Show member pathways
11.98 TLR2 IL4 IL23R IL1B IFNG
34
Show member pathways
11.9 TNF NFKB1 IL1B IFNG
35 11.9 NFKB1 IL4 IL2 IL13 IFNG
36 11.89 TNF IL4 IL2 IL10 IFNG-AS1 IFNG
37 11.87 IFNG IL10 IL1B IL2 TNF
38 11.83 IL4 IL2 IL10 IFNG
39
Show member pathways
11.81 IFNG IL2 IL4 TNF
40 11.8 TNF NFKB1 IL1B
41 11.8 IL2 IL10 IFNG
42
Show member pathways
11.8 TNF NFKB1 IL2 IL1B IFNG
43 11.79 TNF IL4 IL1B IL13
44 11.79 IFNG IL1B IL2 IL23R IL4 NFKB1
45 11.78 TNF NFKB1 IL1B IL10
46 11.76 TNF IL4 IL23R IL2 IL1B IL13
47 11.75 NFKB1 IL2 IFNG
48 11.71 TNF NFKB1 IL10
49 11.69 STAT6 IL4 IL10
50 11.68 HLA-DRB1 IFNG IL10 IL2 IL4 NFKB1

GO Terms for Ulcerative Colitis

Biological processes related to Ulcerative Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.63 TNF TLR2 STAT6 NOD2 NFKB1 IL4
2 signal transduction GO:0007165 10.6 HLA-DRB1 IFNG IL10 IL13 IL1B IL4
3 positive regulation of gene expression GO:0010628 10.5 TNF TLR2 IL4 IL1B IL13 IFNG
4 inflammatory response GO:0006954 10.45 IL13 IL1B IL23R NFKB1 TLR2 TNF
5 cellular response to lipopolysaccharide GO:0071222 10.28 TNF NOD2 NFKB1 IL1B IL10
6 defense response to Gram-positive bacterium GO:0050830 10.24 TNF TLR2 NOD2 IL1B
7 positive regulation of type II interferon production GO:0032729 10.23 IL1B IL2 IL23R TNF
8 negative regulation of inflammatory response GO:0050728 10.21 IL10 IL13 IL2 IL4 NFKB1
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.2 TNF TLR2 NOD2 IL1B
10 regulation of insulin secretion GO:0050796 10.19 TNF IL1B IFNG
11 positive regulation of B cell proliferation GO:0030890 10.19 IL13 IL2 IL4
12 MAPK cascade GO:0000165 10.19 TNF NOD2 NFKB1 IL1B
13 negative regulation of type II interferon production GO:0032689 10.19 NOD2 IL10 HLA-DRB1
14 positive regulation of interleukin-8 production GO:0032757 10.19 TNF TLR2 NOD2 IL1B
15 positive regulation of nitric oxide biosynthetic process GO:0045429 10.18 TNF IL1B IFNG
16 lipopolysaccharide-mediated signaling pathway GO:0031663 10.17 TNF TLR2 IL1B
17 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.17 IL1B IL2 IL4
18 negative regulation of endothelial cell apoptotic process GO:2000352 10.16 IL4 IL13 IL10
19 positive regulation of cytokine production GO:0001819 10.16 TNF IL1B IL10 IFNG
20 JNK cascade GO:0007254 10.15 IL1B NFKB1 NOD2 TNF
21 positive regulation of immunoglobulin production GO:0002639 10.13 IL2 IL13 IL10
22 positive regulation of phagocytosis GO:0050766 10.13 TNF NOD2 IL1B IFNG
23 immune response GO:0006955 10.13 TNF TLR2 IL4 IL2 IL1B IL13
24 positive regulation of interleukin-17 production GO:0032740 10.12 IL2 IL23R NOD2
25 positive regulation of osteoclast differentiation GO:0045672 10.12 TNF IL23R IFNG
26 positive regulation of T cell proliferation GO:0042102 10.12 IL4 IL23R IL2 IL1B
27 positive regulation of inflammatory response GO:0050729 10.1 TNF TLR2 IL2 IL1B IFNG
28 negative regulation of interleukin-12 production GO:0032695 10.09 IL10 NFKB1 NOD2
29 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.08 IFNG NOD2 TLR2
30 positive regulation of interleukin-6 production GO:0032755 10.07 IFNG IL1B NOD2 TLR2 TNF
31 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.06 IFNG IL1B TNF
32 positive regulation of interleukin-12 production GO:0032735 10.06 IFNG IL23R NOD2 TLR2
33 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.05 TNF NOD2 H19
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.04 TNF IL1B IL10
35 positive regulation of chemokine production GO:0032722 10.04 TNF TLR2 IL1B IFNG
36 astrocyte activation GO:0048143 10.03 TNF IL1B IFNG
37 positive regulation of interleukin-10 production GO:0032733 10.03 TLR2 NOD2 IL4 IL13
38 neuroinflammatory response GO:0150076 10.02 IL4 IFNG
39 toll-like receptor 2 signaling pathway GO:0034134 10.02 TLR2 NOD2
40 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 10.01 TNF NOD2
41 negative regulation of cytokine production involved in immune response GO:0002719 10.01 IL10 TNF
42 positive regulation of mononuclear cell migration GO:0071677 10.01 IL4 TNF
43 positive regulation of MHC class II biosynthetic process GO:0045348 10.01 IL4 IL10 IFNG
44 positive regulation of fever generation GO:0031622 10 TNF IL1B
45 regulation of isotype switching GO:0045191 9.99 IL4 IL10
46 negative regulation of interleukin-18 production GO:0032701 9.99 NOD2 IL10
47 sequestering of triglyceride GO:0030730 9.98 TNF IL1B
48 positive regulation of isotype switching to IgE isotypes GO:0048295 9.97 IL4 STAT6
49 positive regulation of nitrogen compound metabolic process GO:0051173 9.97 IFNG TNF
50 positive regulation of plasma cell differentiation GO:1900100 9.96 IL10 IL2

Molecular functions related to Ulcerative Colitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.47 TNF IL4 IL2 IL1B IL13 IL10

Sources for Ulcerative Colitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....